Skip to main content
. 2020 Mar 2;12(3):172–179. doi: 10.14740/jocmr4079

Table 2. Serum Uric Acid Level, Serum Uric Acid/Creatinine Ratio and Serum Bilirubin Levels According to Clinical Characteristics of Parkinson’s Disease.

Total cases (N) SUA (µmol/L) SUA/SCr ratio Total bilirubin (µmol/L) Indirect bilirubin (µmol/L)
PD disease severity (based on H&Y stage)
  Mild (1 - 2) 36 315.74 ± 81.76 4.20 ± 0.88 7.65 (6.71 - 8.72)a 4.28 (3.68 - 4.97)c
  Moderate (2.5 - 3) 11 269.82 ± 65.06 3.71 ± 0.80 8.72 (6.89 - 11.04)b 4.93 (3.79 - 6.42)d
  Severe (4 - 5) 14 301.65 ± 93.94 4.24 ± 0.99 5.56 (4.46 - 6.94) 2.96 (2.20 - 4.00)
  P value 0.222 0.271 0.010 0.014
PD disease duration (years)
  < 2 years 9 321.85 ± 56.54 4.10 ± 0.45 7.70 (6.04 - 9.80) 4.08 (2.89 - 5.77)
  ≥ 2 years 52 301.17 ± 86.32 4.12 ± 0.96 7.21 (6.41 - 8.11) 4.03 (3.51 - 4.62)
  P value 0.556 0.936 0.669 0.906
Motor symptom subtypes
  PIGD 44 297.94 ± 89.27 3.99 ± 0.89 7.09 (6.33 - 7.93) 3.94 (3.44 - 4.50)
  Tremor 10 321.19 ± 46.33 4.55 ± 0.82 8.96 (6.28 - 12.77) 4.81 (3.09 - 7.50)
  P value 0.343 0.079 0.082 0.235

Data are presented as mean ± SD and geometric mean (95% CI). The analysis was controlled by age and co-morbidities. PD: Parkinson’s disease; H&Y: Hoehn-Yahr; PIGD: postural instability/gait difficulty; SUA: serum uric acid; SUA/SCr: serum uric acid/serum creatinine. aP = 0.009 (total bilirubin; mild vs. severe disease); bP = 0.005 (total bilirubin, moderate vs. severe disease); cP = 0.012 (indirect bilirubin, mild vs. severe disease); dP = 0.008 (indirect bilirubin, moderate vs. severe disease). a-dAnalyzed by Fisher’s least significant difference (LSD) test.